Pay in 4 interest-free payments of $6.02 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
These usually resolve on their own but should still be monitored
(2) The Human Evidence Gap No completed, peer-reviewed Phase II or Phase III randomized controlled trials in humans have been published as of July 2025
The standard BPC-157 dosage is 250-500 mcg injected subcutaneously once or twice daily for 4-8 weeks, adjusted for injury type, body weight, and reconstitution concentration
Brain Research Bulletin, 176, 139-146
If this continues consistently, it can cause the brain to age and can increase the risk of conditions such as: Parkinsons disease Huntingtons disease Alzheimers disease Studies suggest that individuals with these conditions have lower glutathione levels, leading many to believe that sufficient glutathione levels can delay the onset of these conditions (2)
Data on file, Catalyst Pharmaceuticals
